Evolución de mujeres con osteoporosis tratadas durante más de tres años

Revista Espa?ola de Enfermedades Metabólicas óseas Pub Date : 2009-07-01 DOI:10.1016/S1132-8460(09)73228-3

J.A. Olmo Fernández-Delgado , M. Canteras Jordana

{"title":"Evolución de mujeres con osteoporosis tratadas durante más de tres años","authors":"J.A. Olmo Fernández-Delgado , M. Canteras Jordana","doi":"10.1016/S1132-8460(09)73228-3","DOIUrl":null,"url":null,"abstract":"<div><p>We are going to show the progress of 41 postmenopausal patients who have followed treatment for more than three years (86 months). Assessing several factors such as: development of the bone mineral density (BMD), adherence to therapeutic treatment, incidence of fractures and risk factors. Thirty five patients (85%) showed increases of the BMD in the spine with an average increase of 21%, and presented statistic changes (p<0.005); 63% presented statistic changes in the hip but with not significant increases. Thirteen patients showed some fracture through fragility and 6 of them suffered more than one episode. By order of frequency: vertebral (spinal) fractures 8 (19.5%), radius 5 (12%), epiphysis of humerus 3 (7, 5%) and hip 2 (5%).</p><p>The most used treatment was alendronate (71%), followed by raloxifene (58%) and risedronate (54%). Using the Morisky test, the 48% of the patients were reliable.</p><p>We have found correlation between increases of the BMD and risk of fracture, not being found related to other risk factors.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 3","pages":"Pages 45-50"},"PeriodicalIF":0.0000,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73228-3","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espa?ola de Enfermedades Metabólicas óseas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1132846009732283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

We are going to show the progress of 41 postmenopausal patients who have followed treatment for more than three years (86 months). Assessing several factors such as: development of the bone mineral density (BMD), adherence to therapeutic treatment, incidence of fractures and risk factors. Thirty five patients (85%) showed increases of the BMD in the spine with an average increase of 21%, and presented statistic changes (p < 0.005); 63% presented statistic changes in the hip but with not significant increases. Thirteen patients showed some fracture through fragility and 6 of them suffered more than one episode. By order of frequency: vertebral (spinal) fractures 8 (19.5%), radius 5 (12%), epiphysis of humerus 3 (7, 5%) and hip 2 (5%).

The most used treatment was alendronate (71%), followed by raloxifene (58%) and risedronate (54%). Using the Morisky test, the 48% of the patients were reliable.

We have found correlation between increases of the BMD and risk of fracture, not being found related to other risk factors.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗3年以上女性骨质疏松症的演变

我们将展示41名绝经后患者的治疗进展，这些患者已接受治疗超过3年(86个月)。评估几个因素，如:骨密度(BMD)的发展，治疗依从性，骨折发生率和危险因素。35例(85%)患者脊柱骨密度升高，平均升高21%，有统计学变化(p <0.005);63%的患者髋部有统计学变化，但无明显增高。13例患者出现脆性骨折，其中6例发生一次以上骨折。按发生频率排序:椎体(脊柱)骨折8例(19.5%)，桡骨骨折5例(12%)，肱骨骨骺骨折3例(7.5%)，髋关节骨折2例(5%)。使用最多的是阿仑膦酸钠(71%)，其次是雷洛昔芬(58%)和利塞膦酸钠(54%)。使用莫里斯基测试，48%的患者是可靠的。我们发现骨密度的增加与骨折风险之间存在相关性，而没有发现与其他危险因素相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Revista Espa?ola de Enfermedades Metabólicas óseas

自引率

0.00%

发文量